7-氯-5,6-二甲基-[1,2,4]三唑并[1,5-A]嘧啶 | 89793-29-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 中文名称: 7-氯-5,6-二甲基-[1,2,4]三唑并[1,5-A]嘧啶
• 英文名称: 7-chloro-5,6-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine
• 英文别名: 7-Chlor-5,6-dimethyl-s-triazolo<1,5-a>pyrimidin
• CAS: 89793-29-3
• 化学式: C₇H₇ClN₄
• mdl: MFCD08899395
• 分子量: 182.612
• InChiKey: RPHBQCUEWQSJTD-UHFFFAOYSA-N

物化性质

• 熔点：
  155 °C
• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-1-(4-(三氟甲基)苯基)乙胺盐酸盐 、 7-氯-5,6-二甲基-[1,2,4]三唑并[1,5-A]嘧啶 在 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 为溶剂， 生成 5,6-dimethyl-N-{(1S)-1-[4-(trifluoromethyl)phenyl]ethyl}[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
  参考文献：
  名称：

  [EN] SUBSTITUTED TRIAZOLO BICYCLICCOMPOUNDS AS PDE2 INHIBITORS
  [FR] BICYCLO-COMPOSÉS DE TRIAZOLE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE PDE2

  摘要：

  本发明涉及一种用于治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病的式（I）的取代三唑杂双环化合物，该化合物可用作治疗神经系统和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能不足或基底神经节功能障碍相关的化合物的用途。

  公开号：

  WO2017000277A1
• 作为产物：
  描述：

  5,6-DIMETHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-OL 在 三氯氧磷 作用下， 生成 7-氯-5,6-二甲基-[1,2,4]三唑并[1,5-A]嘧啶
  参考文献：
  名称：

  Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitors with Potent and Selective Activity against the Malaria Parasite Plasmodium falciparum

  摘要：

  A Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor that is potent (K(I) = 15 nM) and species-selective (>5000-fold over the human enzyme) was identified by high-throughput screening. The substituted triazolopyrimidine and its structural analogues were produced by an inexpensive three-step synthesis, and the series showed good association between PfDHODH inhibition and parasite toxicity. This study has identified the first nanomolar PfDHODH inhibitor with potent antimalarial activity in whole cells (EC(50) = 79 nM).

  DOI：

  10.1021/jm8001026

文献信息

• FAT ACCUMULATION INHIBITORY AGENTS
  申请人：SUMITOMO CHEMICAL COMPANY LIMITED

  公开号：EP1149835A1

  公开（公告）日：2001-10-31

  Aminopyrimidine derivatives represented by general formula: wherein R1 is a hydrogen atom, an alkyl group, an alkenyl group, etc.; R2 and R3 are a hydrogen atom, a halogen atom, an alkyl group, an alkenyl group, etc.; R5 is a hydrogen atom, an alkyl group, etc.; R6 is a C1 to C12 alkyl group, a C2-C12 alkenyl group, etc.; X is a nitrogen atom, CH, etc., can suppress the accumulation of fat in fat cells and are thus effective for the prophylaxis and treatment of various disorders accompanied by increased adipose tissues.

  由通式代表的氨基嘧啶衍生物： 其中R1为氢原子、烷基、烯基等；R2和R3为氢原子、卤素原子、烷基、烯基等；R5为氢原子、烷基等；R6为C1～C12烷基、C2～C12烯基等；X为氮原子、CH等，可抑制脂肪细胞中脂肪的堆积，因此可有效预防和治疗伴随脂肪组织增加的各种疾病。
• Substituted triazolo bicyclic compounds as PDE2 inhibitors
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US10357481B2

  公开（公告）日：2019-07-23

  The present invention is directed to substituted triazolo bicyclic compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及式 I 的取代三唑并双环化合物，其可作为治疗剂用于治疗与磷酸二酯酶 2 (PDE2)相关的中枢神经系统疾病。本发明还涉及使用此类化合物治疗神经和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能低下或基底节功能障碍相关的疾病。
• SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS
  申请人：MORRIELLO Gregori J.

  公开号：US20180169072A1

  公开（公告）日：2018-06-21

  The present invention is directed to substituted triazolo bicyclic compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.